<DOC>
	<DOC>NCT00088634</DOC>
	<brief_summary>A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia</brief_summary>
	<brief_title>A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia</brief_title>
	<detailed_description>Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from the Positive and Negative Syndrome Scale (PANSS).</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Satisfy DSMIV criteria for schizophrenia as established by SCIDCV The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception The patient has used an investigational drug within the past 30 days The patient has participated in a previous study of this compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>